Zacks Investment Research · Jul 6, 2023
Bellerophon Therapeutics (BLPH) Dips More Than Broader Markets: What You Should Know
In the latest trading session, Bellerophon Therapeutics (BLPH) closed at $0.69, marking a -1.78% move from the previous day.
NASDAQ · BLPH
Bellerophon Therapeutics, Inc.
Healthcare · Biotechnology
$0.01
Down-$0.01 (-36.84%)
Updated Sep 13, 2026, 2:00 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 146.79K
- P/E ratio
- -0.01
- Dividend yield
- 158.08%
- 52-week range
- — – —
- Volume
- 1.57K
- Avg. volume
- 13.29K
Price performance
BLPH price history
1M range · 0 trading sessions · Daily adjusted prices
BLPH does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest BLPH news
The latest Smart Investors Daily articles mentioning BLPH.
Stock researchCompany · Overview
BLPH research
Overview
Company profile and research snapshot.
Company profile
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Hold
- Average target
- $2.04
- Implied upside
- —
- Analysts
- 6
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 6, 2023 | HC Wainwright & Co. | Buy | — |
| Jun 6, 2023 | Laidlaw & Co. | Hold | — |
| May 17, 2023 | HC Wainwright & Co. | Buy | — |
| May 9, 2023 | Laidlaw & Co. | Buy | — |
| Apr 4, 2023 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Zacks Investment Research · Jun 29, 2023
Bellerophon Therapeutics (BLPH) Stock Sinks As Market Gains: What You Should Know
Bellerophon Therapeutics (BLPH) closed the most recent trading day at $0.68, moving -1.93% from the previous trading session.
Benzinga · Jun 6, 2023
The Latest Analyst Ratings for Bellerophon Therapeutics
Bellerophon Therapeutics (NASDAQ:BLPH) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 0 0 0 0 Last 30D 1 0 0 0 0 1M Ago 2 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 1 0 0 0 0 According to 4 analyst offering 12-month price targets in the last 3 months, Bellerophon Therapeutics has an average price target of $24.25 with a high of $35.00 and a low of $2.00. Below is a summary of how these 4 analysts rated Bellerophon Therapeutics over the past 3 months. The greater the number of bullish ratings, the more positive ...Full story available on Benzinga.com
Zacks Investment Research · Jun 6, 2023
Bellerophon (BLPH) Down 87% as Lung Disease Candidate Fails
Bellerophon's (BLPH) shares fall as a late-stage study of INOpulse to treat fibrotic interstitial lung disease fails to meet its primary endpoint.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
